Patients with pleural mesothelioma that can not be surgically removed will receive
durvalumab, in combination with standard chemotherapy of pemetrexed and cisplatin as
Durvalumab is a type of drug called a monoclonal antibody (a type of protein). Laboratory
tests show that it works by allowing the immune system to detect your cancer and reactivates
the immune response. This may help to slow down the growth of cancer or may cause cancer
cells to die.
The purpose of this study is to see whether adding durvalumab to standard chemotherapy will
improve overall survival (OS).